Shein Shares Slide 9% in Hong Kong IPO Debut 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Add as a preferred source on Google
SAN DIEGO, March 13, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.
|
|||
CrownBio provides the world’s largest collection of Patient-Derived Xenograft (PDX) models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments. Phanes will gain access to CrownBio’s clinically relevant CDX models, exclusive PDX models and robust in vitro assays to propel their innovative drug discovery pipeline.
Dr. Ming Wang, President and CEO of Phanes Therapeutics, expressed enthusiasm about this partnership, “We are an innovative drug discovery company with a robust pipeline and need access to top notch in vivo pharmacology efficacy models to quickly evaluate and advance our lead molecules. We are very glad to partner with CrownBio. They have very unique MuPrime™ models, as well as Humanized GEMMs (HuGEMM™) and Patient-Derived Xenograft (PDX) models for our oncology programs. We look forward to a productive partnership.”
“We are very pleased that Phanes Therapeutics has selected us as a trusted partner to advance their leading-edge oncology compounds,” said Laurie Heilmann, CrownBio’s Chief Business Officer. “Our unique capabilities will help Phanes efficiently and thoroughly assess drugs in their pipeline to identify and advance candidates showing the most promise for improved treatment of cancer.”
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
About Phanes Therapeutics
Phanes Therapeutics is a biotech company with strong innovative drug discovery and development programs in metabolic complications and oncology areas. It was founded by former Janssen/J&J Vice President Ming Wang, PhD, MBA. The company focuses exclusively on biologics drug discovery with multiple first-in-class and best-in-class molecules in its pipeline. For more information on Phanes, please visit www.phanesthera.com.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
